Amide proton transfer weighted (APTw) imaging based radiomics allows for the differentiation of gliomas from metastases

Sartoretti, Elisabeth; Sartoretti, Thomas; Wyss, Michael; Reischauer, Carolin; Smoorenburg, Luuk van; Binkert, Christoph A.; Sartoretti–Schefer, Sabine; Mannil, Manoj

doi:10.1038/s41598-021-85168-8

Cited by 30 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All but two of them extracted radiomic features from MRI sequences, while one evaluated features from CT [ 25 ] and one extracted features from PET [ 24 ]. In all but three studies [ 25 , 46 , 58 ], the glioma group consisted of patients with grade IV glioma (GBM). Six studies extracted radiomic features from contrast-enhanced T1-weighted MRI scans [ 20 , 31 , 38 , 54 , 55 , 59 ].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis

Brancato¹,

Cerrone²,

Lavitrano

et al. 2022

Cancers

View full text Add to dashboard Cite

Radiomics is a promising tool that may increase the value of imaging in differential diagnosis (DDx) of glioma. However, implementation in clinical practice is still distant and concerns have been raised regarding the methodological quality of radiomic studies. Therefore, we aimed to systematically review the current status of radiomic studies concerning glioma DDx, also using the radiomics quality score (RQS) to assess the quality of the methodology used in each study. A systematic literature search was performed to identify original articles focused on the use of radiomics for glioma DDx from 2015. Methodological quality was assessed using the RQS tool. Spearman’s correlation (ρ) analysis was performed to explore whether RQS was correlated with journal metrics and the characteristics of the studies. Finally, 42 articles were selected for the systematic qualitative analysis. Selected articles were grouped and summarized in terms of those on DDx between glioma and primary central nervous system lymphoma, those aiming at differentiating glioma from brain metastases, and those based on DDx of glioma and other brain diseases. Median RQS was 8.71 out 36, with a mean RQS of all studies of 24.21%. Our study revealed that, despite promising and encouraging results, current studies on radiomics for glioma DDx still lack the quality required to allow its introduction into clinical practice. This work could provide new insights and help to reach a consensus on the use of the radiomic approach for glioma DDx.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis

Brancato¹,

Cerrone²,

Lavitrano

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Amide proton transfer (APT)-weighted imaging is a type of chemical exchange saturation transfer (CEST)-based imaging with a heightened sensitivity to endogenous mobile proteins and peptides, and it has shown promise in characterizing brain tumors [ 146 , 147 , 148 , 149 ]. The difference (increase) in the contents of mobile protons and peptides in the tumor tissue relative to the surrounding parenchyma leads to an increased APT signal [ 150 ], with high-grade/malignant brain tumors exhibiting a high degree of protein content. There is an expanding role for APT-weighted imaging in the detection, grading, evaluation of recurrence versus post-treatment effects, and the identification of the genetic markers of brain tumors.…”

Section: Mri Techniquesmentioning

confidence: 99%

Advanced Neuroimaging Approaches to Pediatric Brain Tumors

Nikam¹,

Yue²,

Kaur³

et al. 2022

Cancers

View full text Add to dashboard Cite

Central nervous system tumors are the most common pediatric solid tumors; they are also the most lethal. Unlike adults, childhood brain tumors are mostly primary in origin and differ in type, location and molecular signature. Tumor characteristics (incidence, location, and type) vary with age. Children present with a variety of symptoms, making early accurate diagnosis challenging. Neuroimaging is key in the initial diagnosis and monitoring of pediatric brain tumors. Conventional anatomic imaging approaches (computed tomography (CT) and magnetic resonance imaging (MRI)) are useful for tumor detection but have limited utility differentiating tumor types and grades. Advanced MRI techniques (diffusion-weighed imaging, diffusion tensor imaging, functional MRI, arterial spin labeling perfusion imaging, MR spectroscopy, and MR elastography) provide additional and improved structural and functional information. Combined with positron emission tomography (PET) and single-photon emission CT (SPECT), advanced techniques provide functional information on tumor metabolism and physiology through the use of radiotracer probes. Radiomics and radiogenomics offer promising insight into the prediction of tumor subtype, post-treatment response to treatment, and prognostication. In this paper, a brief review of pediatric brain cancers, by type, is provided with a comprehensive description of advanced imaging techniques including clinical applications that are currently utilized for the assessment and evaluation of pediatric brain tumors.

show abstract

“…It can be applied to study alterations in proteins, peptides, cellularity, proliferation, necrosis, IDH and MGMT, and metabolites. In addition to APT and NOE, other CEST contrasts have been explored to further study the underlying molecular alterations, including the regional alterations, in brain tumors, especially with the aid of radiomics [6,12].…”

Section: Multiple Cest Contrast In Brain Tumorsmentioning

confidence: 99%

Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges

et al. 2022

View full text Add to dashboard Cite

Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) detects molecules in their natural forms in a sensitive and non-invasive manner. This makes it a robust approach to assess brain tumors and related molecular alterations using endogenous molecules, such as proteins/peptides, and drugs approved for clinical use. In this review, we will discuss the promises of CEST MRI in the identification of tumors, tumor grading, detecting molecular alterations related to isocitrate dehydrogenase (IDH) and O-6-methylguanine-DNA methyltransferase (MGMT), assessment of treatment effects, and using multiple contrasts of CEST to develop theranostic approaches for cancer treatments. Promising applications include (i) using the CEST contrast of amide protons of proteins/peptides to detect brain tumors, such as glioblastoma multiforme (GBM) and low-grade gliomas; (ii) using multiple CEST contrasts for tumor stratification, and (iii) evaluation of the efficacy of drug delivery without the need of metallic or radioactive labels. These promising applications have raised enthusiasm, however, the use of CEST MRI is not trivial. CEST contrast depends on the pulse sequences, saturation parameters, methods used to analyze the CEST spectrum (i.e., Z-spectrum), and, importantly, how to interpret changes in CEST contrast and related molecular alterations in the brain. Emerging pulse sequence designs and data analysis approaches, including those assisted with deep learning, have enhanced the capability of CEST MRI in detecting molecules in brain tumors. CEST has become a specific marker for tumor grading and has the potential for prognosis and theranostics in brain tumors. With increasing understanding of the technical aspects and associated molecular alterations detected by CEST MRI, this young field is expected to have wide clinical applications in the near future.

show abstract

Amide proton transfer weighted (APTw) imaging based radiomics allows for the differentiation of gliomas from metastases

Cited by 30 publications

References 37 publications

A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis

A Systematic Review of the Current Status and Quality of Radiomics for Glioma Differential Diagnosis

Advanced Neuroimaging Approaches to Pediatric Brain Tumors

Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges

Contact Info

Product

Resources

About